B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus

Adelle Dawson, Sanjay Jeyaseelan, Andrew D. Morris, Allan D. Struthers

    Research output: Contribution to journalArticlepeer-review

    16 Citations (Scopus)

    Abstract

    Cardiovascular risk scores are available but are often not calculated in busy clinics for numerous practical reasons. B-type natriuretic peptide (BNP) may be an alternative way of identifying subjects who have a high total cardiovascular risk score. We compared BNP level with Framingham 10-year Risk Scores for coronary heart disease and stroke and New Zealand Cardiovascular Risk Scores in 231 patients who had type 2 diabetes and no preexisting coronary heart disease or stroke. There was a significant correlation between log BNP and 10-year risk for coronary heart disease and stroke, and there were significantly higher BNP levels in those who had high cardiovascular risk as assessed by the New Zealand Risk Score. BNP may be a useful way of measuring total cardiovascular risk, thus having the potential to better target the most aggressive primary preventive therapies toward the most needy.
    Original languageEnglish
    Pages (from-to)933-934
    Number of pages2
    JournalAmerican Journal of Cardiology
    Volume96
    Issue number7
    DOIs
    Publication statusPublished - Oct 2005

    Fingerprint Dive into the research topics of 'B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus'. Together they form a unique fingerprint.

    Cite this